Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T22:31:42.612Z.
Calculation as of: 2026-10-06T22:31:42.612Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b5b90a83151b8a074e07f32cd5a8423240b7dae761ecc8f52934664174c7f924
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$34.97M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$32.93M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Elutia Inc (ELUT) | $34.35M | N/A | N/A | N/A | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $34.97M | N/A | N/A | N/A | N/A |
| Scilex Holding Company (SCLX)vs › | $33.63M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.61M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.29M | N/A | N/A | N/A | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $35.52M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $35.76M | N/A | 6.76x | 19.14x | 45.56x |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $32.93M | N/A | N/A | N/A | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $35.84M | N/A | N/A | N/A | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $35.84M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
